AI Innovations in Cancer Prediction

This chapter discusses the implications of 23andMe's bankruptcy and AstraZeneca's collaboration with an AI startup to enhance cancer survival prediction through innovative imaging tools. It highlights the development of the IPRO model, which outperforms traditional methods in forecasting outcomes for lung cancer patients and emphasizes the importance of using advanced data analysis techniques. The chapter further explores the potential of AI in clinical trials to improve treatment assessments and decision-making in oncology.